



OFFICE of the DEPUTY PRIME MINISTER
MINISTRY for HEALTH
15, PALAZZO CASTELLANIA, MERCHANTS STREET, VALLETTA, MALTA

DH CIRCULAR No. 28/2021

DH 472/2021

6th May 2021

Attention All: Consultants
Medical Doctors
Pharmacists
Pharmacy Technicians
Nurses

Re: Lapatinib 250mg Tablets

As part of the Government's ongoing plan to increase the availability of free cancer treatment, it is being brought to your attention that lapatinib 250mg tablets are now available on the Government Formulary List for in-patient and out-patient use.

Lapatinib 250mg tablets can be prescribed by Consultant Oncologists for breast cancer as per protocol 109 (Annex 1) attached.

For your attention please.

Dr. Denis Vella Baldacchino
Chief Medical Officer

Lapatinib 250mg tablets

Prescriber Criteria: Consultant Oncologist

Out-patient and In-patient use:

1. Malignant Diseases

For use with trastuzumab and with/without a taxane (docetaxel or paclitaxel) in adult patients with HER2- positive advanced or metastatic breast cancer who develop brain metastases or cardiotoxicity.

Duration of Approval:

1year